SBIR Phase I: Fully Screen Printed Electric Cell-Substrate Impedance Sensing Toxicity Assay

SBIR 第一阶段：全丝网印刷电池基板阻抗传感毒性测定

• 批准号: 2111981
• 负责人: Rashi Sultania
• 金额: $ 25.6万
• 依托单位: ORTUVO LLC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-06-01 至 2022-11-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2111981&HistoricalAwards=false
• 关键词: SBIR; Phase; Fully; Screen; Printed

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to develop a new product testing tool to evaluate potential human toxicity of products in development. Current practices that test a product’s effects on humans consist of lengthy, expensive, and harmful animal studies. Given the cost, many animal toxicity screenings often happen in later product development stages – at which point millions of development dollars have already been spent. Major financial losses follow unfavorable screening results. Specifically, this technology will be developed with the intention to not only save millions of dollars downstream, but also maintain animal welfare and ethics in the product development process across industries. Compared to the current market offerings by others, this novel cell toxicity assay is intuitive and easy to manage with respect to time and the number of samples, while providing a rapid, accurate assessment. The global toxicology testing market is projected to reach $14.4 billion by 2025. This Small Business Innovation Research (SBIR) Phase I project is aimed at developing a novel, scalable in vitro toxicity assay that leverages a cellular-electrode interface bioprinting technology. Toxicological testing occurs toward the end of product development of a drug or consumer product after millions of dollars have already been poured into R&D. These in vivo screens are expensive, harmful to animals, and have the potential to kill products after years of pre-market development. Bioprinting has emerged as a promising new approach for biofabricating models and systems for in vitro toxicology screening in an attempt to address the ethical and financial burden aforementioned. Yet, despite revolutionary potential, traditional bioprinting has technical and commercial drawbacks (e.g. cell damage, low throughput, high cost, inflexible). This proposal is designed to address those drawbacks by developing 1) a novel method to biofabricate tissues using an innovative bioprinting technique and 2) an integration of electrode sensors to quantitatively measure cell health and viability via electrical signal output correlations. Experimental success of tissue fabrication and electrode-cellular measurements will be determined by greater than 80% of cellular viability following novel bioprinting method and a correlation value of r 0.6 between electrical impedance readings and canonical molecular toxicity analyses.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这项小型企业创新研究（SBIR）I阶段项目的更广泛的影响/商业潜力是开发一种新的产品测试工具来评估产品中潜在的人类毒性。当前测试产品对人类影响的实践包括冗长，昂贵和有害的动物研究。鉴于成本，许多动物毒性筛查经常在以后的产品开发阶段进行 - 此时已经花费了数百万美元。重大财务损失遵循不利的筛查结果。具体而言，该技术将不仅打算在下游节省数百万美元，而且还要在整个行业的产品开发过程中维持动物福利和道德。与其他人当前的市场产品相比，这种新型细胞毒性评估是直观的，并且易于在时间和样品数量方面易于管理，同时提供了快速，准确的评估。预计到2025年，全球毒理学测试市场预计将达到144亿美元。这项小型企业创新研究（SBIR）I阶段项目旨在开发一种可扩展的可扩展体外毒性评估，利用细胞 - 电极界面生物构图技术。毒理学测试是在产品或消费产品的产品开发结束后进行的，此后已经将数百万美元倒入研发中。这些体内屏幕很昂贵，对动物有害，并且有可能杀死多年的市场前开发。生物印刷已成为一种承诺的新方法，用于生物制作模型和体外毒理学筛查系统，以试图解决终止之前的道德和财务燃烧。然而，目的地革命潜力，传统的生物打印具有技术和商业弊端（例如，细胞损害，低吞吐量，高成本，僵化）。该建议旨在通过开发1）使用创新的生物打印技术生物制作时间的新方法来解决这些缺点，以及2）电极传感器的整合，以通过电信号输出相关性来定量测量细胞健康和生存能力。在新型生物启示方法和电阻抗读数和规范分子毒性分析之间的相关值和相关值之后，组织制造和电极细胞测量的实验成功将由大于80％的细胞生存力确定，并且在使用NSF的法定任务中，通过评估了Intellitia的支持和众多的基础。